3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms, Second Primary
1
NSCLC
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Gastro Intestinal Stromal Tumor
1
Endometrial Neoplasms
1
Congenital Abnormalities
1
Asymptomatic Brain Metastases
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Rituximab
5
Lenalidomide
5
Cytarabine
5
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Tyrosine Kinase Inhibitors
×
1 year
×
Clear all
No trials found.